Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
2024 SS
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
-
2020 WS
-
2020 SS
-
2019 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma : Digital Gene Expression Analysis and Supervised Machine Learning ModelIn: International Journal of Molecular Sciences (IJMS) Jg. 24 (2023) Nr. 15, 12426Online Volltext: dx.doi.org/ (Open Access)
-
Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer : A Matched-Pair AnalysisIn: Oncology Research and Treatment Jg. 46 (2023) Nr. 3, S. 100 - 104Online Volltext: dx.doi.org/
-
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerIn: Therapeutic Advances in Medical Oncology Jg. 13 (2021)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. 002262Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Digital gene expression analysis of epithelioid and sarcomatoid mesothelioma reveals differences in immunogenicityIn: Cancers Jg. 13 (2021) Nr. 8, S. 1761Online Volltext: dx.doi.org/ (Open Access)
-
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma : Final results of the MARC-2 trialIn: International Journal of Cancer Jg. 148 (2021) Nr. 7, S. 1685 - 1694Online Volltext: dx.doi.org/ (Open Access)
-
Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment : A retrospective studyIn: Translational Lung Cancer Research Jg. 10 (2021) Nr. 7, S. 3030 - 3042Online Volltext: dx.doi.org/ (Open Access)
-
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinomaIn: Future Oncology Jg. 17 (2021) Nr. 30, S. 3965 - 3976Online Volltext: dx.doi.org/ (Open Access)
-
Thrombospondin‐2 and ldh are putative predictive biomarkers for treatment with everolimus in second‐line metastatic clear cell renal cell carcinoma (Marc‐2 study)In: Cancers Jg. 13 (2021) Nr. 11, 2594Online Volltext: dx.doi.org/ (Open Access)
-
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 2, S. 191 - 194Online Volltext: dx.doi.org/ (Open Access)
-
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesotheliomaIn: Cancer Management and Research Jg. 11 (2019) S. 8711 - 8720Online Volltext: dx.doi.org/ (Open Access)
-
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroIn: BMC Cancer Jg. 19 (2019) Nr. 1, 108Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 144 (2018) Nr. 12, S. 2457 - 2463Online Volltext: dx.doi.org/
-
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapyIn: OncoTarget Jg. 9 (2018) Nr. 32, S. 22254 - 22268Online Volltext: dx.doi.org/ (Open Access)
-
Inhibition of MDM2 via Nutlin-3A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53In: Journal of Oncology (2018) 1986982Online Volltext: dx.doi.org/ (Open Access)
-
Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine TumorsIn: Technology in Cancer Research & Treatment (TCRT) Jg. 17 (2018)Online Volltext: dx.doi.org/ (Open Access)
-
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung AdenocarcinomaIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 6, S. e879 - e884Online Volltext: dx.doi.org/
-
Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients : updated ORR, PFS and OS data from the BIRCH studyIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 5, S. 220Online Volltext: dx.doi.org/
-
Factors for the long-term Survival of Patients with NSCLC in the Stage of oligometastatic Disease after definitive Local TherapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. Suppl. 1, S. 58
-
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesotheliomaIn: OncoTarget Jg. 8 (2017) Nr. 23, S. 37502 - 37510Online Volltext: dx.doi.org/ (Open Access)
-
Growth patterns of pulmonary metastases : Should we adjust resection techniques to primary histology and size?In: European Journal of Cardio-Thoracic Surgery Jg. 52 (2017) Nr. 1, S. 39 - 46Online Volltext: dx.doi.org/
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, S. 54 - 64Online Volltext: dx.doi.org/ (Open Access)
-
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 24, S. 2781 - 2789Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung AdenocarcinomaIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. Suppl. 1, S. S1201 - S1201
-
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesotheliomaIn: Virchows Archiv Jg. 470 (2017) Nr. 6, S. 627 - 637Online Volltext: dx.doi.org/
-
ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter TechnologyIn: PLoS ONE Jg. 11 (2016) Nr. 11, S. e0165181Online Volltext: dx.doi.org/ (Open Access)
-
Cisplatin in the modern era : The backbone of first-line chemotherapy for non-small cell lung cancerIn: Cancer Treatment Reviews Jg. 44 (2016) S. 42 - 50Online Volltext: dx.doi.org/
-
Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancerIn: Journal of Thoracic Disease Jg. 8 (2016) Nr. 10, S. E1254 - E1256Online Volltext: dx.doi.org/ (Open Access)
-
Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcomeIn: OncoTarget Jg. 7 (2016) Nr. 15, S. 20166 - 20179Online Volltext: dx.doi.org/ (Open Access)
-
Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumorsIn: Journal of Cancer Jg. 7 (2016) Nr. 15, S. 2165 - 2172Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
OSNA : a fast molecular test based on CK19 mRNA concentration for assessment of EBUS-TBNA samples in lung cancer patientsIn: Clinical Lung Cancer Jg. 17 (2016) Nr. 3, S. 198 - 204Online Volltext: dx.doi.org/
-
Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH) : Updated Efficacy and Exploratory Biomarker Results: Topic: Medical OncologyIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. Supplement 11, S. 251 - S.252Online Volltext: dx.doi.org/ (Open Access)
-
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based ChemotherapyIn: Journal of Cancer Jg. 7 (2016) Nr. 13, S. 1915 - 1925Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesotheliomaIn: OncoTarget Jg. 7 (2016) Nr. 14, S. 18713 - 18721Online Volltext: dx.doi.org/
-
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasIn: Lung Cancer Jg. 88 (2015) Nr. 1, S. 34 - 41Online Volltext: dx.doi.org/
-
Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysisIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 24690 - 24698Online Volltext: dx.doi.org/ (Open Access)
-
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53In: British Journal of Cancer (BJC) Jg. 112 (2015) Nr. 5, S. 883 - 890Online Volltext: dx.doi.org/ (Open Access)
-
Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour groupIn: British Journal of Cancer (BJC) Jg. 113 (2015) Nr. 12, S. 1704 - 1711Online Volltext: dx.doi.org/ (Open Access)
-
SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString)In: Future Oncology Jg. 11 (2015) Nr. 7, S. 1027 - 1036Online Volltext: dx.doi.org/
-
Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesisIn: Journal of Cancer Jg. 5 (2014) Nr. 6, S. 465 - 471Online Volltext: dx.doi.org/ (Open Access)
-
Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung : results of a profiling studyIn: Modern Pathology Jg. 27 (2014) Nr. 12, S. 1632 - 1640Online Volltext: dx.doi.org/
-
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancerIn: Future Oncology Jg. 10 (2014) Nr. 5, S. 823 - 833Online Volltext: dx.doi.org/
-
Gene expression analysis of the 26S proteasome subunit PSMB4 reveals significant upregulation, different expression and association with proliferation in human pulmonary neuroendocrine tumoursIn: Journal of Cancer Jg. 5 (2014) Nr. 8, S. 646 - 654Online Volltext: dx.doi.org/ (Open Access)
-
Mdm2 protein expression is strongly associated with survival in malignant pleural mesotheliomaIn: Future Oncology Jg. 10 (2014) Nr. 6, S. 995 - 1005Online Volltext: dx.doi.org/
-
Prätherapeutische Biomarker des Lungenkarzinoms unter besonderer Berücksichtigung der BronchoskopieIn: Pneumologie Jg. 68 (2014) Nr. 11, S. 719 - 726Online Volltext: dx.doi.org/
-
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvementsIn: Current Opinion in Oncology Jg. 26 (2014) Nr. 2, S. 171 - 181Online Volltext: dx.doi.org/
-
ERCC1, MLH1, MSH2, MSH6, and βiII-tubulin: Resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesotheliomaIn: Clinical Lung Cancer Jg. 14 (2013) Nr. 5, S. 558 - 567Online Volltext: dx.doi.org/
-
Midterm changes in quality of life : A prospective evaluation after open pulmonary metastasectomyIn: The Annals of Thoracic Surgery Jg. 95 (2013) Nr. 3, S. 1006 - 1011Online Volltext: dx.doi.org/
-
Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancerIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 11, S. 2461 - 2468Online Volltext: dx.doi.org/
-
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 1, S. 19 - 30Online Volltext: dx.doi.org/
-
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 4, S. 766 - 767Online Volltext: dx.doi.org/ (Open Access)
-
Distribution pattern of metastases and their associations with survival of malignant pleural mesothelioma patients undergoing different treatment modalitiesIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 140
-
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, S. 1440 - 1448Online Volltext: dx.doi.org/ (Open Access)
-
Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based ChemotherapyIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, Suppl. 4, S. S211 - S212
-
Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) expression in metastatic non-small cell lung cancer patients treated with pemetrexed-based chemotherapyIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 34
-
Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung CancerIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 6, S. 982 - 992Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerIn: British Journal of Cancer (BJC) Jg. 107 (2012) Nr. 5, S. 823 - 830Online Volltext: dx.doi.org/ (Open Access)
-
10-year long-term survival (LTS) of induction (IND) chemotherapy (CTX) with three cycles cisplatin(P)/paclitaxel(T) followed by concurrent (CC) chemoradiation (CTX/RTX) P/Etoposide (ETO)/45 GY (1.5 GY BID) plus surgery (S) - A multicenter phase-II trial (Cistaxol)In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. 494
-
Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 4, S. 14
-
Long-term survival (LTS) and competing risks within a prospective multicenter german randomized trial comparing induction (IND) chemotherapy (CTX) followed by concurrent (CC) chemoradiation (CTX/RTX) plus surgery (S) (= Trimodality) supplemented by PCI VEIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. 495
-
Polo-like kinase 1 inhibitors in mono- and combination therapies : A new strategy for treating malignanciesIn: Expert Review of Anticancer Therapy Jg. 11 (2011) Nr. 7, S. 1117 - 1132Online Volltext: dx.doi.org/
-
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7024Online Volltext: dx.doi.org/
-
Very Late and Isolated Leptomeningeal Relapse of a Pulmonary Adenocarcinoma Presenting as DementiaIn: Onkologie Jg. 34 (2011) Nr. 6, S. 316 - 320Online Volltext: dx.doi.org/
-
Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from val30met mutation with no clinical signs of polyneuropathyIn: Circulation: Heart Failure Jg. 2 (2009) Nr. 5, S. 512 - 515Online Volltext: dx.doi.org/ (Open Access)
-
Intraventricular Chemotherapy for Leptomeningeal Carcinomatosis from Lung Cancer : A Feasible and Beneficial Treatment Option?In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 5, S. 523 - 524Online Volltext: dx.doi.org/
-
Clinical Platform for Research into molecular Testing, Treatment and Disease Progression in Patients with Lung Cancer (CRISP) : First Real-World Evidence on Stage II and III NSCLC in Germany - AIO-TRK-0315In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. S11 - S12
-
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP) : First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. S935 - S936Online Volltext: dx.doi.org/ (Open Access)
-
Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9050 - 9050Online Volltext: dx.doi.org/
-
Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition : Real-world evidenceIn: Annals of Oncology Jg. 31 (2020) S. 876Online Volltext: dx.doi.org/ (Open Access)
-
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with PembrolizumabIn: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. Suppl. 1, S. 243
-
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S353Online Volltext: dx.doi.org/ (Open Access) -
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
ESMO Virtual Congress 2020, 19.-21.09- und 16.-18.10.2020,In: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S1076 - S1077Online Volltext: dx.doi.org/ (Open Access) -
Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S482Online Volltext: dx.doi.org/ (Open Access)
-
Immunohistochemically Detectable Metallothionein Expression in Malignant Pleural Mesotheliomas is Strongly Associated with Early Failure to Platin-Based Chemotherapy
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie Jg. 73 (2019) Nr. 02, S. 110 - 111Online Volltext: dx.doi.org/ -
Processing Escapes : an Alternative Explanation for Immune Therapy Resistance
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie Jg. 73 (2019) Nr. 02, S. 111 - 112Online Volltext: dx.doi.org/ -
BRCAness phenotype is common in MPM and is associated with response to olaparib in vitro
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 175Online Volltext: dx.doi.org/ (Open Access) -
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 115Online Volltext: dx.doi.org/ (Open Access) -
Inhibition of MDM2 via Nutlin-3A : A potential therapeutic approach for pleural mesotheliomas with MDM2-induced inactivation of P53
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 175Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 108Online Volltext: dx.doi.org/ (Open Access) -
Mass Spectrometry based Methylation Analysis of MDM2, CDKN2A, RB1, TP53 and TP73 and Associations to MDM2 Overexpression in Malignant Pleural mesothelioma
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 115Online Volltext: dx.doi.org/ (Open Access) -
Processing escape mechanisms through alterated proteasomal cleavage of epitopes affects immune response in pulmonary neuroendocrine tumors
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 176Online Volltext: dx.doi.org/ (Open Access) -
Identification of prognostic and predictive biomarkers in malignant pleural mesothelioma in 134 patients from two research sites (Berlin and Essen)
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 123Online Volltext: dx.doi.org/ -
Competing risks analysis and long-term survival (LTS) of patients (PTS) with locally advanced (LAD) stage III non-small- cell lung cancer (NSCLC) treated on sequential trimodality (TM) trials
14th World Conference on Lung Cancer (WCLC), July 03 - 07, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S376 - S377 -
Increased Thymidylate Synthase (TS) Gene Copy Number in NSCLCIn: Journal of Thoracic Oncology Jg. 5 (2010) Nr. 5 Suppl. 1, S. S56Online Volltext: dx.doi.org/
-
Prädiktive Biomarker für Platin- und Pemetrexed-basierte Chemotherapien bei malignen pulmonalen und pleuralen TumorenDuisburg ; Essen (2017) 1 CD-ROM
-
PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 226 - 227Online Volltext: dx.doi.org/ (Open Access) -
PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S1135Online Volltext: dx.doi.org/ (Open Access) -
Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC – a retrospective analysis in a real-world setting
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 229Online Volltext: dx.doi.org/ (Open Access)